AstraZeneca plc may never recover, is it time to buy Hikma Pharmaceuticals plc?

As AstraZeneca plc (LON: AZN) struggles it may be time to buy Hikma Pharmaceuticals plc (LON: HIK) instead.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The pharmaceutical industry is one of the market’s most defensive sectors.

However, not all pharma groups are created equal, and the fortunes of two of the industry’s biggest players, AstraZeneca (LSE: AZN) and Hikma Pharmaceuticals (LSE: HIK) couldn’t be more different.

Differing outlooks

Hikma is one of the London market’s greatest success stories. Hikma specialises in the production of generic, low-cost drugs that have lost patent protection. The company has seen a surge in sales and profitability over the past few years as a wave of high-profile drugs have come off patent across the pharmaceutical industry.

For example, if Hikma meets City earnings forecasts for 2017, the company’s pre-tax profit will have grown by 270% over seven years or around 24% per annum. City analysts expect the company to report earnings per share growth of 38% for 2017 and based on this forecast the company is trading at a 2017 P/E of 20.2 and PEG ratio of 0.5 — a PEG ratio below one indicates that the company’s shares offer growth at a reasonable price.

Hikma’s shares only offer a token dividend yield of 1%, although the payout is covered four-and-a-half times by earnings per share, so there’s plenty of room for further growth.

A positive spin

Astra’s management tried to put a positive spin on the company’s first quarter figures but reading between the lines it’s clear the company is struggling.

On a headline basis, core operating profit fell by 12% to $1.6bn and revenues increased by 1% to $6.13bn. The company blamed higher levels of research spending for most of the decline in profit. However, reading through the figures, it becomes clear that profits were flattered by $646m as a result of lower amortisation charges and externalisation deals that raised $550m. These one-off benefits won’t last forever and the year is only really just getting started for Astra as the company is set to lose the exclusive manufacturing rights for its leading Crestor drug later in 2016.

As yet, it’s impossible to tell how much the loss of these exclusive rights will cost the company although it’s possible to get some idea.

Specifically, in 2014 Crestor and another of Astra’s leading treatments, Nexium, accounted for a third of the company’s revenue or $9.2bn. Nexium came off patent in mid-2014 and during its first full year without patent protection, Astra’s sales of the drug fell by more than 30%.

Astra’s management has warned that the company’s profits will fall by a mid-to-single-digit percentage this year off the back of falling sales and so far it’s unclear how quickly the group will be able to recover its composure from the decline of Crestor and Nexium. It’s also not possible to tell how quickly Astra’s Crestor sales will slide this year after they lose patent protection.

The bottom line

With so much uncertainty surrounding Astra’s outlook, Hikma looks to be the better investment despite the company’s lofty valuation.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

2 UK stocks with recovering profit margins

This writer considers a pair of UK stocks with very different share price trajectories following the pandemic. Would he buy…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Will Trump’s tariffs squeeze this FTSE 100 giant’s profits?

Our writer looks at how the latest news around US tariffs might impact FTSE 100 company Diageo. Should he be…

Read more »

Investing Articles

Up 95%, is this FTSE winner the best high-yield star for me to buy now?

Do we have to choose between share price growth and high-yield dividends? In this case, over the past year, it…

Read more »

Investing Articles

Up 140% and rocketing out of the FTSE 250! Is it too late for me to buy this red-hot stock?

Miniature war games hero Games Workshop has outgrown the FTSE 250 and is hammering at the door of the UK's…

Read more »

Investing Articles

If I invest £10,000 in Taylor Wimpey shares, how much passive income will I receive?

Taylor Wimpey shares have fallen and are now paying a huge dividend. How much might I receive by investing a…

Read more »

Index Funds text carved in stone background
Investing Articles

Why I choose to invest in individual stocks rather than an index fund

Our writer examines the differences between stock picking and investing in index funds and why he feels there’s more to…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Here’s the dividend forecast for Sage Group shares through to 2026!

The dividend on Sage shares has risen for 12 straight years. Can the FTSE 100 company keep its proud record…

Read more »

Happy African American Man Hugging New Car In Auto Dealership
Investing Articles

Will 2025 be make or break for this FTSE 250 stock hitting the headlines?

One of the FTSE 250's worst performers in 2024 has just issued another profit warning, but could 2025 mark the…

Read more »